ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2052

Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population
Abstract Number: 2053

Current State and Completeness of Reporting Clinical Prediction Models Using Machine Learning in Systemic Lupus Erythematosus: A Systematic Review
Abstract Number: 2054

Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process
Abstract Number: 2055

SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?
Abstract Number: 2056

Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
Abstract Number: 2057

Outpatient Visit Adherence and Impact on Disease-related Morbidity in Childhood-onset Systemic Lupus Erythematosus (cSLE)
Abstract Number: 2058

Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
Abstract Number: 2059

Association of Hydroxychloroquine with the Incidence of Infectious Disease in Systemic Lupus Erythematosus: Data from the LUNA Registry
Abstract Number: 2060

Increased Risk of Adverse Renal Outcomes in Patients of African Ancestry with Systemic Lupus Erythematosus (SLE) – Role of APOL1
Abstract Number: 2061

Impact of Time to Remission, Flares and Exposure to Immunosuppressives on the Development of Advanced Chronic Kidney Disease (Stage IV or Worse) in Lupus Nephritis
Abstract Number: 2062

Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US
Abstract Number: 2063

Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
Abstract Number: 2064

Trajectories of Disease Activity in a Longitudinal Registry of Pediatric SLE
Abstract Number: 2065

Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
Abstract Number: 2066

Measuring Sexual Dysfunction as an Indicator of Frailty in Systemic Lupus Erythematosus Population

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].